Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for EYSUVIS™
September 10 2020 - 8:00AM
Business Wire
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical
company focused on the discovery, development and commercialization
of innovative therapies for diseases of the eye, today announced
that it will host a key opinion leader symposium on the unmet need
in dry eye disease and the potential for EYSUVIS™ as a short-term
treatment for the signs and symptoms of the disease. The event will
be held virtually on Thursday, September 17, 2020, beginning at
8:00 a.m. ET.
Scheduled to speak at the event are Edward J. Holland, M.D.,
Director of Cornea Services at Cincinnati Eye Institute and
Professor of Ophthalmology at the University of Cincinnati and
Kelly K. Nichols, O.D., M.P.H., Ph.D., F.A.A.O., Dean of the School
of Optometry at the University of Alabama at Birmingham.
Additionally, Kala management will present an update on launch
planning for EYSUVIS. A New Drug Applicaton (NDA) for EYSUVIS is
currently under review by the U.S. Food and Drug Administration
(FDA) with a Prescription Drug User Fee Act (PDUFA) goal date of
October 30, 2020. If approved, Kala expects to launch EYSUVIS
before year-end.
To access the event, please dial 866-300-4091 (domestic callers)
or 703-736-7433 (international callers) five minutes prior to the
start of the event and provide the conference ID 7985989.
Additionally, a live webcast and subsequent archived recording of
the presentation will be available under “Events” in the
“Investors” section of the Kala website at http://kalarx.com
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the discovery,
development and commercialization of innovative therapies for
diseases of the eye. Kala has applied its AMPPLIFY® mucus
penetrating particle Drug Delivery Technology to a corticosteroid,
loteprednol etabonate (LE), designed for ocular applications,
resulting in the January 2019 launch of INVELTYS® (loteprednol
etabonate ophthalmic suspension) 1% and its investigational product
candidate, EYSUVIS™ (loteprednol etabonate ophthalmic suspension)
0.25%, for which a New Drug Application (NDA) is under review by
the United States Food and Drug Administration (FDA) with a
Prescription Drug User Fee Act (PDUFA) goal date set for October
30, 2020.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200910005003/en/
Investor Contact: Hannah Deresiewicz
hannah.deresiewicz@sternir.com 212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Mar 2024 to Apr 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Apr 2023 to Apr 2024